Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.

Autor: Jensen I; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany., Heine J; Department of Neurology, Hannover Medical School, Hanover, Germany., Ruf VC; Center for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany., Compta Y; Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Catalonia, Spain., Porcel LM; Neurology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain., Troakes C; Basic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom., Vamanu A; Basic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom., Downes S; Basic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom., Irwin D; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Cohen J; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Lee EB; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.; Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Nilsson C; Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden., Englund E; Department of Clinical Sciences, Division of Pathology instead of Neurology, Lund University, Lund, Sweden., Nemati M; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany., Katzdobler S; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany., Levin J; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Strasse 17, Munich, Germany., Pantelyat A; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Seemiller J; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Berger S; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., van Swieten J; Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands., Dopper E; Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands., Rozenmuller A; Department of Pathology, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands., Kovacs GG; Laboratory Medicine Program and Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.; Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada., Bendahan N; Edmond J. Safra Program in Parkinson's Disease and the Rossy Progressive Supranuclear Palsy Centre, Division of Neurology, Toronto Western Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada., Lang AE; Edmond J. Safra Program in Parkinson's Disease and the Rossy Progressive Supranuclear Palsy Centre, Division of Neurology, Toronto Western Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada., Herms J; Center for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Strasse 17, Munich, Germany., Höglinger G; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Strasse 17, Munich, Germany., Hopfner F; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Jazyk: angličtina
Zdroj: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2024 Sep; Vol. 39 (9), pp. 1514-1522. Date of Electronic Publication: 2024 Jun 07.
DOI: 10.1002/mds.29879
Abstrakt: Background: Multiple system atrophy is a neurodegenerative disease with α-synuclein aggregation in glial cytoplasmic inclusions, leading to dysautonomia, parkinsonism, and cerebellar ataxia.
Objective: The aim of this study was to validate the accuracy of the International Parkinson and Movement Disorder Society Multiple System Atrophy clinical diagnostic criteria, particularly considering the impact of the newly introduced brain magnetic resonance imaging (MRI) markers.
Methods: Diagnostic accuracy of the clinical diagnostic criteria for multiple system atrophy was estimated retrospectively in autopsy-confirmed patients with multiple system atrophy, Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration.
Results: We identified a total of 240 patients. Sensitivity of the clinically probable criteria was moderate at symptom onset but improved with disease duration (year 1: 9%, year 3: 39%, final ante mortem record: 77%), whereas their specificity remained consistently high (99%-100% throughout). Sensitivity of the clinically established criteria was low during the first 3 years (1%-9%), with mild improvement at the final ante mortem record (22%), whereas specificity remained high (99%-100% throughout). When MRI features were excluded from the clinically established criteria, their sensitivity increased considerably (year 1: 3%, year 3: 22%, final ante mortem record: 48%), and their specificity was not compromised (99%-100% throughout).
Conclusions: The International Parkinson and Movement Disorder Society multiple system atrophy diagnostic criteria showed consistently high specificity and low to moderate sensitivity throughout the disease course. The MRI markers for the clinically established criteria reduced their sensitivity without improving specificity. Combining clinically probable and clinically established criteria, but disregarding MRI features, yielded the best sensitivity with excellent specificity and may be most appropriate to select patients for therapeutic trials. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
(© 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)
Databáze: MEDLINE
Externí odkaz: